Oncolytics Biotech (ONCY) Payables (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Payables of $3.6 million for Q4 2025, down 13.33% year-over-year from $4.1 million in Q4 2024, and down 31.62% quarter-over-quarter from $5.2 million in Q3 2025.
Oncolytics Biotech (ONCY) Payables (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Payables for 17 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Payables fell 13.33% year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (down 13.33% YoY), while the FY2025 annual figure was $3.6 million, down 15.06% from the prior year.
- Payables declined to $3.6 million in Q4 2025 per ONCY's latest filing, from $5.2 million in the prior quarter.
- Across five years, Payables topped out at $7.3 million in Q3 2023 and bottomed at $1.6 million in Q4 2021.
- Historically, Payables has averaged $3.1 million across 5 years, with a median of $2.8 million in 2022.
- Annual changes were most pronounced in 2023 — Payables surged 180.89% — and 2024, when it slumped 55.15%.
- Oncolytics Biotech's Payables stood at $1.6 million in 2021, then surged by 69.41% to $2.7 million in 2022, then rose by 0.86% to $2.8 million in 2023, then jumped by 49.13% to $4.1 million in 2024, then slipped by 13.33% to $3.6 million in 2025.
- Business Quant data shows ONCY's Payables at $3.6 million in Q4 2025, $5.2 million in Q3 2025, and $4.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 35.57 Mn |
| 10 | Oncolytics Biotech | 98.14 Mn | 98.14 Mn | - | 3.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.41 Mn |
| Dec 31, 2025 | 3.58 Mn |
| Sep 30, 2025 | 5.24 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Dec 31, 2024 | 4.13 Mn |
| Sep 30, 2024 | 3.26 Mn |
| Jun 30, 2024 | 4.02 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 2.77 Mn |
| Sep 30, 2023 | 7.26 Mn |
| Jun 30, 2023 | 1.87 Mn |
| Mar 31, 2023 | 1.69 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 2.58 Mn |
| Jun 30, 2022 | 1.74 Mn |
| Mar 31, 2022 | 1.67 Mn |
| Dec 31, 2021 | 1.62 Mn |
| Sep 30, 2021 | 1.94 Mn |
| Jun 30, 2021 | 1.91 Mn |